Study Published In NEJM Shows Nplate(R) Significantly Reduces Treatment Failure And Splenectomy Rate In Patients With Chronic ITP

Links shared publicly online about this topic.

  • 725
    total visits

Study Published In NEJM Shows Nplate(R) Significantly Reduces Treatment Failure And Splenectomy Rate In Patients With Chronic ITP

medicalnewstoday.com —

Amgen Inc. (NASDAQ: AMGN) announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomi

View full resource at medicalnewstoday.com

Tags: Amgen

  • Share

Most Recently Shared on November 15, 2010 at 4:05 pm By:

mnt_vaccines MNT Vaccines

Study Published In NEJM Shows Nplate(R) Significantly Reduces Treatment Failure And Splenectomy Rate In Patients With ... http://mnt.to/3MtN

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Blood MNT Blood

Advertisement